Panelists discuss how advancements in topical PDE4 inhibitors, particularly roflumilast and crisaborole, are reshaping the management of atopic dermatitis by offering new nonsteroidal options with distinct mechanisms of action and safety profiles.
EP. 1: Evolution of Topical Treatment for AD
November 8th 2024Panelists discuss the current landscape of topical treatments for atopic dermatitis, focusing on the evolution of nonsteroidal options over the past decade, and explain the mechanism of action of PDE4 inhibitors in specifically targeting inflammatory pathways associated with the condition.